Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q3 2022 · 10-Q
Revenue$357.90K$357.90K+14.0% vs Q3 2021 Net Income-$10.54M-$10.54MN/M vs Q3 2021 EPS Diluted-$0.05-$0.05N/M vs Q3 2021 Operating Income-$10,540,200N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$12,045,400— Margins · derivedOperating margin-2945.0%−1257.3 pt vs Q3 2021
Net margin-2943.6%−1256.1 pt vs Q3 2021
ended Dec 31, 2021 · filed Feb 10, 2022 · 41 d after period end